Participated · Series D · Apr 2017

Epic Sciences develops and markets liquid‑biopsy diagnostics to guide therapy selection and monitor disease progression in prostate and breast cancers. Its flagship offering, DefineMBC, is a three‑component blood‑based biopsy that reports circulating tumor cell detection, HER2 and ER protein expression and single‑cell sequencing for ERBB2 amplification, alongside a 56‑gene plasma cell‑free DNA panel including ERBB2 and PIK3CA and tumor mutational burden. The company leverages proprietary cell analysis and cell‑free analysis in a CAP/CLIA‑accredited laboratory and provides Comprehensive Cancer Profiling to pharmaceutical partners and major cancer centers. Epic has delivered DefineMBC results to 700 patients and their oncologists through a Clinical Experience Program. In the past twelve months Epic raised $67 million across a $43M Series F and a $24M Series G to fund commercialization of DefineMBC. Proceeds are being used to build commercial infrastructure (sales, product marketing, customer service, medical affairs, payer markets and billing) and to generate additional concordance and outcomes data. Epic Sciences is a diagnostics company based in San Diego that develops and markets liquid biopsy tests and multi-omic cancer profiling to guide therapy selection and monitor disease progression in prostate and breast cancers. Its liquid biopsy platform combines proprietary cell analysis capabilities with cell-free DNA analysis to provide more complete, efficient cancer profiling. The company operates a full-service CAP/CLIA-accredited laboratory and provides research support services, partnering with pharmaceutical companies and major cancer centers worldwide. Epic's DefineMBC™ blood-based test for comprehensively characterizing metastatic breast cancer has been reporting patient results since April 2022 and uses multi-analyte methods to detect circulating tumor cells, assess protein expression (HER2, ER), determine intra-cell CNVs, and identify SNVs, indels, fusions, CNVs, MSI and TMB from plasma. The company plans to use the new capital to continue advancing its multi-omic platform and to expand operations in single-cell sequencing and data analytics infrastructure. Lloyd Sanders serves as President and CEO. Epic Sciences develops diagnostics and decision-support analytics that match patients’ individual cancer cells to individualized drug therapies using computer vision and machine learning. The company’s technology is aimed at prolonging life and reducing treatment costs by avoiding ineffective therapies. Epic is advancing oncology decision-support services in its pipeline and plans to accelerate clinical studies to validate and commercialize those offerings. Proceeds from the recent financing are expected to fund those clinical studies and support execution of its long-term growth plan. Epic is based in San Diego and positions its products for value-based, individualized cancer care. Epic Sciences, based in San Diego, develops blood-based liquid biopsy tests designed to predict drug response in cancer patients. Its core platform is the proprietary No Cell Left Behind technology and a portfolio of blood-based tests that characterize rare circulating cells using digital imaging and big data analytics. The company plans to use the funds to accelerate clinical studies for oncology tests in its pipeline and to enhance No Cell Left Behind to include characterization of rare leukocyte cell populations. These enhancements are intended to drive transformative insights into the cellular drivers of response or resistance to key drug classes such as immuno-oncology therapies. Epic recently partnered with Genomic Health to commercialize the OncotypeDx AR-V7 Nucleus Detect test and to leverage Genomic Health’s commercial channel and enterprise systems. Murali Prahalad, Ph.D., serves as president and CEO. Epic Sciences develops technology that enables comprehensive characterization of circulating tumor cells (CTCs) from a liquid biopsy to inform therapy selection and detect early signs of drug resistance. The company is led by Murali Prahalad, Ph.D., president and CEO. Epic offers products and offerings aimed at personalizing and advancing the treatment and management of cancer. The company expanded available capital under an existing credit facility, giving it optionality to accelerate expansion of research capabilities and product development efforts. The amended credit facility increases available capacity and extends the financing maturity, improving near‑term liquidity and runway for R&D. Epic is a private diagnostics company based in San Diego, CA.

Participated · Series C · Nov 2016

Tiantian Paiche is a Chinese online used-car trading platform that connects individual buyers with dealers through an online-to-offline (O2O) platform. Led by founder and CEO Weiwei Wang, the company offers a range of car dealership services. The company raised US$100m in a Series C funding round. Backers named in the round included Pagoda Investment, Tencent and BitAuto Technology, among others. Tiantian Paiche said it will use the proceeds to enhance business operations, improve customer user experience and continue to expand its market share. The capital is intended to support growth and product improvements across its O2O used-car marketplace.